NR5A2 and metabolic dysfunction-associated steatotic liver disease: One such NR is the liver receptor homolog 1 (LRH‐1, a.k.a. NR5A2), which has emerged as a promising drug target for diseases like diabetes, pancreatic cancer, non‐alcoholic fatty liver disease and metabolic syndrome.13, 14, 15, 16, 17, 18